Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:45 UTC |
---|
HMDB ID | HMDB0014803 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Nilutamide |
---|
Description | Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. |
---|
Structure | CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20) |
---|
Synonyms | Value | Source |
---|
5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin | ChEBI | Nilandron | ChEBI | Nilutamida | ChEBI | Nilutamidum | ChEBI | 5,5-Dimethyl-3-(a,a,a-trifluoro-4-nitro-m-tolyl)hydantoin | Generator | 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin | Generator | 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione | HMDB | Hoechst brand OF nilutamide | HMDB | Aventis behring brand OF nilutamide | HMDB | Aventis brand OF nilutamide | HMDB | Anandron | HMDB |
|
---|
Chemical Formula | C12H10F3N3O4 |
---|
Average Molecular Weight | 317.2207 |
---|
Monoisotopic Molecular Weight | 317.062340438 |
---|
IUPAC Name | 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione |
---|
Traditional Name | nilutamide |
---|
CAS Registry Number | 63612-50-0 |
---|
SMILES | CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F |
---|
InChI Identifier | InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20) |
---|
InChI Key | XWXYUMMDTVBTOU-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Azolidines |
---|
Sub Class | Imidazolidines |
---|
Direct Parent | Phenylhydantoins |
---|
Alternative Parents | |
---|
Substituents | - 3-phenylhydantoin
- Phenylimidazolidine
- Alpha-amino acid or derivatives
- Trifluoromethylbenzene
- Nitrobenzene
- Nitroaromatic compound
- N-acyl urea
- Ureide
- Monocyclic benzene moiety
- Benzenoid
- Dicarboximide
- Organic nitro compound
- C-nitro compound
- Carbonic acid derivative
- Urea
- Azacycle
- Organic 1,3-dipolar compound
- Carboxylic acid derivative
- Propargyl-type 1,3-dipolar organic compound
- Allyl-type 1,3-dipolar organic compound
- Organic oxoazanium
- Carbonyl group
- Organohalogen compound
- Organic zwitterion
- Organic oxygen compound
- Hydrocarbon derivative
- Alkyl fluoride
- Organic nitrogen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Organic oxide
- Alkyl halide
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0042 g/L | Not Available | LogP | 1.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Nilutamide,1TMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C | 2044.1 | Semi standard non polar | 33892256 | Nilutamide,1TMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C | 2157.3 | Standard non polar | 33892256 | Nilutamide,1TMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C | 2480.6 | Standard polar | 33892256 | Nilutamide,1TBDMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C(C)(C)C | 2322.7 | Semi standard non polar | 33892256 | Nilutamide,1TBDMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C(C)(C)C | 2357.6 | Standard non polar | 33892256 | Nilutamide,1TBDMS,isomer #1 | CC1(C)C(=O)N(C2=CC=C([N+](=O)[O-])C(C(F)(F)F)=C2)C(=O)N1[Si](C)(C)C(C)(C)C | 2522.2 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Nilutamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a59-9051000000-b212093377487cffc158 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Nilutamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 30V, Negative-QTOF | splash10-0600-0094000000-0991ece9f9d42b94c643 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 15V, Negative-QTOF | splash10-014i-0019000000-7989a507a8031f03f612 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 45V, Negative-QTOF | splash10-00di-0090000000-1d63c70e06fcd4c6d922 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 60V, Negative-QTOF | splash10-0kmi-0390000000-05fc687a7f642e06e60a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 60V, Positive-QTOF | splash10-0kmi-0390000000-e2d42b542bf6dc07d5c0 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 75V, Negative-QTOF | splash10-0zfr-1970000000-f1091bfdddddc602902c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nilutamide 90V, Negative-QTOF | splash10-0lz9-1920000000-14b04987997234218267 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 10V, Positive-QTOF | splash10-014i-0009000000-f4acafe069c7fdcf8fc3 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 20V, Positive-QTOF | splash10-0a4i-9025000000-2c79c0bbfc87dd118bd7 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 40V, Positive-QTOF | splash10-0a4l-9000000000-a91f0e83aff94e2bad18 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 10V, Negative-QTOF | splash10-014i-0009000000-19746ba07e5113297e15 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 20V, Negative-QTOF | splash10-014i-4009000000-f2904499b324cc347c22 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nilutamide 40V, Negative-QTOF | splash10-0a4l-9000000000-740d06c64bdf821f7e3d | 2016-08-03 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00665 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00665 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00665 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4337 |
---|
KEGG Compound ID | C08164 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Nilutamide |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 4493 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 7573 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4. [PubMed:12686822 ]
- Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J: Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006 Jun;13(3):81-93. [PubMed:17576447 ]
|
---|